Current disease phase-Chronic phase Page 3 Posts on Medivizor
Navigation Menu

Current disease phase-Chronic phase Posts on Medivizor

Examining complete molecular response to treatment with different doses of imatinib

Posted by on Apr 7, 2017 in Leukemia | 0 comments

In a nutshell This study examined the extent and effect of complete treatment response (on a molecular level) in patients treated with imatinib (Gleevac) for chronic myeloid leukemia (CML). Researchers reported that a high proportion of patients treated with imatinib reached complete molecular remission, particularly when given at a high dose. Complete...

Read More

Peripheral arterial occlusive disease in chronic myeloid leukemia treated with TKI therapy

Posted by on Apr 7, 2017 in Leukemia | 0 comments

In a nutshell This study compared the rates of peripheral arterial occlusive disease (PAOD) in chronic myeloid leukemia (CML) patients treated with different therapies. The authors concluded that nilotinib (Tasigna) was associated with higher rates of PAOD than other treatments. Some background Tyrosine kinase inhibitors (TKIs) are now the...

Read More

Therapy and quality of life in chronic myeloid leukemia

Posted by on Apr 7, 2017 in Leukemia | 0 comments

In a nutshell This study reviewed recent research on the long-term health related quality of life for patients with chronic myeloid leukemia (CML). The authors concluded that while CML patients may now expect to lead long lives, more attention needs to focus on managing treatment side effects. Some background The prognosis for patients with CML...

Read More

Examining bosutinib as a treatment option for patients not responding to multiple first-line tyrosine kinase inhibitors

Posted by on Mar 29, 2017 in Leukemia | 0 comments

In a nutshell This study examined the effectiveness of bosutinib (Bosulif), a tyrosine kinase inhibitor (TKI), after previous treatment with multiple TKIs for chronic myeloid leukemia (CML). Researchers concluded that bosutinib was associated with good effectiveness for CML patients for whom previous TKIs have failed. Some background Targeted...

Read More

Examining treatment outcomes with second-line tyrosine kinase inhibitors over time

Posted by on Mar 16, 2017 in Leukemia | 0 comments

In a nutshell This study examined treatment outcomes in patients with chronic myeloid leukemia (CML) treated with second-line tyrosine kinase inhibitors (TKIs). Researchers concluded that treatment responses with second-line TKIs are stable over time. Patients with less favorable treatment outcomes can be identified early during therapy. Some...

Read More